Registered title, quoted from ClinicalTrials.gov
Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Henan Cancer Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07684950, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Histologically and immunophenotypically confirmed mantle cell lymphoma.
Inclusion criterion 3
Participants of reproductive potential must agree to use effective contraception during study treatment and for 3 months after the last dose of study treatment.
Inclusion criterion 13
Concurrent participation in another clinical study. 3. Prior treatment with any BCL-2 inhibitor. 4. Active central nervous system involvement, including parenchymal or leptomeningeal disease.
Exclusion criterion 2
Eastern Cooperative Oncology Group performance status of 0 to 2.
Inclusion criterion 6
Total bilirubin ≤1.5 × upper limit of normal;
Inclusion criterion 9
Creatinine clearance ≥30 mL/min;
Inclusion criterion 10
Absolute neutrophil count ≥0.5 × 10\^9/L;
Inclusion criterion 11
Platelet count ≥30 × 10\^9/L. Supportive treatment is permitted.
Inclusion criterion 12
Positive human immunodeficiency virus test. 9. Active hepatitis B or hepatitis C infection, except:
Exclusion criterion 6
Pregnant or breastfeeding women. 11. Unable to complete protocol-required study visits or procedures, including follow-up visits, or unable to comply with study requirements.
Exclusion criterion 9
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07684950, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Participants must meet all of the following criteria:
- Age 18 years or older.
- Histologically and immunophenotypically confirmed mantle cell lymphoma.
- At least one measurable lesion.
- Received at least one prior systemic treatment regimen that included a BTK-targeted therapy, including a covalent BTK inhibitor, non-covalent BTK inhibitor, or BTK degrader, and had stable disease, disease progression, or intolerance during or after the most recent BTK-targeted therapy.
- Eastern Cooperative Oncology Group performance status of 0 to 2.
- Adequate hepatic, renal, and bone marrow function, defined as all of the following:
- Aspartate aminotransferase and alanine aminotransferase ≤3 × upper limit of normal;
- Total bilirubin ≤1.5 × upper limit of normal;
- Creatinine clearance ≥30 mL/min;
- Absolute neutrophil count ≥0.5 × 10\^9/L;
- Platelet count ≥30 × 10\^9/L. Supportive treatment is permitted.
- Participants of reproductive potential must agree to use effective contraception during study treatment and for 3 months after the last dose of study treatment.
- Willing and able to comply with study procedures and follow-up assessments.
- Able to understand and voluntarily sign the informed consent form before screening.
Exclusion Criteria:
- 1. Known hypersensitivity to pirtobrutinib, lisaftoclax, or any component or excipient of either study drug.
- Concurrent participation in another clinical study. 3. Prior treatment with any BCL-2 inhibitor. 4. Active central nervous system involvement, including parenchymal or leptomeningeal disease.
- Clinically significant uncontrolled cardiac or cardiovascular disease, or a history of myocardial infarction within 6 months before the planned initiation of pirtobrutinib.
- Uncontrolled active severe systemic bacterial, viral, fungal, or parasitic infection.
- Current treatment with strong CYP3A4 inhibitors or inducers and/or strong P-glycoprotein inhibitors.
- Positive human immunodeficiency virus test. 9. Active hepatitis B or hepatitis C infection, except:
- Participants with detectable hepatitis B virus DNA whose disease is controlled may be enrolled at the investigator's discretion, provided that concurrent antiviral therapy is administered;
- Participants with a history of hepatitis C virus infection who have completed antiviral treatment and have a viral load below the lower limit of quantification may be enrolled.
- Pregnant or breastfeeding women. 11. Unable to complete protocol-required study visits or procedures, including follow-up visits, or unable to comply with study requirements.
- Any other clinically significant current or prior medical condition that, in the investigator's judgment, may pose a risk to participant safety or interfere with study assessments, procedures, or completion.
Quoted from ClinicalTrials.gov, NCT07684950, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07684950, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.